Gilead says its coronavirus treatment remdesivir just succeeded in a crucial study, raising hopes for a first COVID-19 drug




Gilead says its coronavirus treatment remdesivir just succeeded in a crucial study, raising hopes for a first COVID-19 drug
Gilead says its coronavirus treatment remdesivir just succeeded in a crucial study, raising hopes for a first COVID-19 drug  
COMMENTS

More Related News

Why Vaxart
Why Vaxart's Stock Is Trading Higher Today

Vaxart Inc (NASDAQ: VXRT) shares are trading higher on Monday after B Riley FBR initiated coverage on the company's stock with a Buy rating and announced a $22 price target.The company also raised about $90 million in gross proceeds through at-the-market-facility.Vaxart is a biopharmaceutical company. It is focused on the discovery and development of direct-acting antivirals to treat infections that affect patients globally.The company has three product candidates which are; Influenza, Norovirus and RSV Vaccine, an oral fusion protein inhibitor for the treatment and prevention of respiratory syncytial virus (RSV) infections, and BTA074, a topical antiviral treatment in for condyloma...

One in three South Korean COVID-19 patients improve with remdesivir
One in three South Korean COVID-19 patients improve with remdesivir
  • US
  • 2020-07-13 04:32:02Z

One in three South Korean patients seriously ill with COVID-19 showed an improvement in their condition after being given Gilead Sciences Inc's antiviral remdesivir, health authorities said. Remdesivir has been at the forefront of the global battle against COVID-19 after the intravenously administered medicine helped shorten hospital recovery times in a U.S. clinical trial. Several countries including South Korea have added the drug to the list of treatment for the disease caused by the novel coronavirus.

Australia Provisionally Approves Gilead
Australia Provisionally Approves Gilead's Covid-19 Treatment

Australia's Therapeutic Goods Administration (TGA) has granted provisional approval to Gilead Sciences' (GILD) remdesivir ("Veklury") as the first treatment option for COVID-19.It has received provisional approval for use in adults and adolescent patients with severe COVID-19 symptoms who have been hospitalized. Remdesivir will not be available to Australians unless they are severely unwell, requiring oxygen or high-level support to breathe, and in hospital care."Remdesivir is the most promising treatment option so far to reduce hospitalisation time for those suffering from severe coronavirus infections" the TGA states, adding that remdesivir offers the potential to reduce the strain on...

Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk
Gilead Reveals Covid-19 Treatment Remdesivir Reduces Mortality Risk

Gilead Sciences (GILD) has announced encouraging additional data on remdesivir, the company's investigational antiviral for the treatment of COVID-19.The data includes a comparative analysis of the Phase 3 SIMPLE-Severe trial and a real-world retrospective cohort of patients with severe COVID-19."In this analysis, remdesivir was associated with an improvement in clinical recovery and a 62% reduction in the risk of mortality compared with standard of care - an important finding that requires confirmation in prospective clinical trials" the company stated.Separate subgroup analyses from the Phase 3 SIMPLE-Severe trial, including an evaluation of the safety and efficacy of remdesivir across...

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Soccer